CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving?
CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving? Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for […]
Read More